TD Asset Management Inc Lowers Stock Holdings in Biogen Inc. $BIIB

TD Asset Management Inc lowered its position in Biogen Inc. (NASDAQ:BIIB) by 16.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 135,352 shares of the biotechnology company’s stock after selling 25,843 shares during the period. TD Asset Management Inc’s holdings in Biogen were worth $23,821,000 at the end of the most recent quarter.

Other institutional investors have also bought and sold shares of the company. Rothschild Investment LLC raised its holdings in Biogen by 12.3% during the fourth quarter. Rothschild Investment LLC now owns 513 shares of the biotechnology company’s stock valued at $90,000 after acquiring an additional 56 shares during the period. Advisory Services Network LLC boosted its stake in shares of Biogen by 3.9% in the third quarter. Advisory Services Network LLC now owns 1,792 shares of the biotechnology company’s stock worth $251,000 after acquiring an additional 68 shares during the period. Davis Investment Partners LLC grew its position in shares of Biogen by 1.7% during the fourth quarter. Davis Investment Partners LLC now owns 4,374 shares of the biotechnology company’s stock worth $778,000 after purchasing an additional 71 shares in the last quarter. Optas LLC grew its position in shares of Biogen by 4.5% during the fourth quarter. Optas LLC now owns 1,706 shares of the biotechnology company’s stock worth $300,000 after purchasing an additional 73 shares in the last quarter. Finally, CIBC Private Wealth Group LLC raised its stake in Biogen by 8.1% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 1,189 shares of the biotechnology company’s stock valued at $167,000 after purchasing an additional 89 shares during the period. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Biogen Price Performance

Shares of Biogen stock opened at $195.34 on Monday. The firm has a market cap of $28.84 billion, a PE ratio of 20.96 and a beta of 0.20. The stock has a 50 day moving average of $187.60 and a 200 day moving average of $183.46. The company has a current ratio of 3.06, a quick ratio of 2.41 and a debt-to-equity ratio of 0.34. Biogen Inc. has a 12 month low of $121.05 and a 12 month high of $205.97.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Wednesday, April 29th. The biotechnology company reported $3.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.95 by $0.62. The business had revenue of $2.48 billion for the quarter, compared to the consensus estimate of $2.29 billion. Biogen had a return on equity of 12.83% and a net margin of 13.81%.The company’s revenue was up 1.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.02 EPS. Biogen has set its FY 2026 guidance at 14.250-15.250 EPS. On average, research analysts expect that Biogen Inc. will post 14.18 EPS for the current fiscal year.

Biogen News Summary

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Biogen’s salanersen won FDA Breakthrough Therapy Designation for SMA, with early phase 1b data suggesting meaningful motor improvements and a once-yearly dosing profile that could make the therapy stand out commercially. BIIB’s Next-Gen SMA Therapy Salanersen Wins FDA’s Breakthrough Tag
• Positive Sentiment: Biogen also highlighted progress on BIIB115 in post-gene therapy SMA, adding to investor optimism that the company has multiple shots on goal in a key neurodegeneration market. Biogen Advances BIIB115 in Post–Gene Therapy SMA: Early Signals for Long‑Term Growth
• Positive Sentiment: Biogen and UCB presented additional data on dapirolizumab pegol in lupus, showing reduced flare rates and lower steroid use, which supports the drug’s potential in a large autoimmune market. UCB and Biogen build steroid-sparing case for lupus drug
• Neutral Sentiment: Biogen is also facing legal overhang after law firms announced investor investigations and fraud-related claims, which could keep sentiment cautious even as pipeline news improves. BIIB Investors Have Opportunity to Join Biogen Inc. Fraud Investigation with the Schall Law Firm
• Neutral Sentiment: A separate investor alert from Pomerantz also flagged a claims investigation into Biogen, adding another potential risk factor, though it does not yet indicate any formal enforcement action. INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Biogen Inc. – BIIB

Analyst Ratings Changes

A number of research analysts recently commented on the company. Argus raised Biogen to a “hold” rating in a report on Thursday, April 9th. Rothschild & Co Redburn increased their price objective on shares of Biogen from $180.00 to $190.00 in a report on Thursday, April 30th. UBS Group upgraded shares of Biogen from a “neutral” rating to a “buy” rating and lifted their price objective for the company from $185.00 to $225.00 in a research report on Wednesday, April 22nd. Tudor Pickering set a $201.00 target price on shares of Biogen in a research report on Monday, February 9th. Finally, Evercore began coverage on shares of Biogen in a research note on Friday, May 15th. They set an “outperform” rating for the company. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $215.81.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.